What Is the Optimal Surgical Approach to Thymectomy in Myasthenia Gravis?
This meta-analysis of studies comparing 2 or more surgical approaches vs thymectomy aimed to identify the best option for myasthenia gravis patients.
Myasthenia Gravis
Efgartigimod Therapy Well-Tolerated and Efficacious for Generalized Myasthenia Gravis
A team of researchers assessed the safety, efficacy, and tolerability of efgartigimod for the treatment of patients with generalized myasthenia gravis.
AChR Ab Levels Predict 1-Year Immunosuppressive Therapy Success in Myasthenia Gravis
A team of investigators evaluated the relationship between changes in AChR Ab levels induced by immunosuppressive treatment and myasthenia gravis prognosis at 1-year following treatment in patients with the disease.
Efgartigimod Well Tolerated and Effective for Myasthenia Gravis
Efgartigimod may be an effective and well-tolerated treatment option for patients with myasthenia gravis.
Immune Checkpoint Inhibitors Increase Risk of Neurologic Toxicities
Investigators evaluated the characteristics and risk factors for neurologic adverse events associated with immune checkpoint inhibitors.
Tacrolimus Appears Safe, Effective for Drug-Naïve Myasthenia Gravis
Investigators assessed the safety and efficacy of tacrolimus monotherapy as an initial approach for patients with drug-naïve myasthenia gravis.
FDA to Review Efgartigimod for Generalized Myasthenia Gravis
Efgartigimod, an Fc receptor antagonist, reduces disease-causing immunoglobulin G (IgG) antibodies and blocks the IgG recycling process.
New Treatment Recommendations for Myasthenia Gravis
A panel of international experts provided new evidence-based recommendations for the management of myasthenia gravis, including new guidance for thymectomy and medical treatment.
Safety and Efficacy of Eculizumab in Patients with Refractory Myasthenia Gravis
There was a rapid and sustained clinical response in patients treated with eculizumab for anti-acetylcholine receptor-positive refractory generalized myasthenia gravis.
Solifenacin Succinate LS Approved for Neurogenic Detrusor Overactivity
The FDA has approved solifenacin succinate LS oral suspension for the treatment of neurogenic detrusor overactivity in pediatric patients 2 years of age and older.
- Loading...
Loading...
Next post in Neuromuscular Disorders
Loading... 
Loading...